![[Feedback]](/icons/banner/feedbackACT.gif){kind=icon}
![[For Subscribers]](/icons/banner/subscriberACT.gif){kind=icon}
![[Archive]](/icons/banner/archiveACT.gif){kind=icon}
![[Search]](/icons/banner/searchACT.gif){kind=icon}
![[Contents]](/icons/banner/tocACT.gif){kind=icon}
|
|
|
|
|
||
S Schuldiner, S Steiner-Mordoch, R Yelin, SC Wall and G Rudnick
Department of Pharmacology, Yale University School of Medicine, New Haven, CT 06510.
The interaction of fenfluramine, 3,4-methylenedioxymethamphetamine (MDMA), and p-chloroamphetamine (PCA) with the platelet plasma membrane serotonin transporter and the vesicular amine transporter were studied using both transport and binding measurements. Fenfluramine is apparently a substrate for the plasma membrane transporter, and consequently inhibits both serotonin transport and imipramine binding. Moreover, fenfluramine exchanges with internal [3H]serotonin in a plasma membrane transporter-mediated reaction that requires NaCl and is blocked by imipramine. These properties are similar to those of MDMA and PCA as previously described. In adrenal chromaffin granule membrane vesicles containing the vesicular amine transporter, fenfluramine inhibited serotonin transport and dissipated the transmembrane pH difference (delta pH) that drives amine uptake. The use of [3H]reserpine-binding measurements to determine drug interaction with the vesicular amine transporter allowed assessment of the relative ability of MDMA, PCA, and fenfluramine to bind to the substrate site of the vesicular transporter. These measurements permit a distinction between inhibition of vesicular serotonin transport by directly blocking vesicular amine transport and by dissipating delta pH. The results indicate that MDMA and fenfluramine inhibit by both mechanisms but PCA dissipates delta pH without blocking vesicular amine transport directly.
This article has been cited by other articles:
|
|
 |
|
  W. C. Samms, R. P. Perera, D. S. Wimalasena, and K. Wimalasena Perturbation of Dopamine Metabolism by 3-Amino-2-(4'-halophenyl)propenes Leads to Increased Oxidative Stress and Apoptotic SH-SY5Y Cell Death Mol. Pharmacol., September 1, 2007; 72(3): 744 - 752. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. S. Partilla, A. G. Dempsey, A. S. Nagpal, B. E. Blough, M. H. Baumann, and R. B. Rothman Interaction of Amphetamines and Related Compounds at the Vesicular Monoamine Transporter J. Pharmacol. Exp. Ther., October 1, 2006; 319(1): 237 - 246. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. Zolkowska, R. B. Rothman, and M. H. Baumann Amphetamine Analogs Increase Plasma Serotonin: Implications for Cardiac and Pulmonary Disease J. Pharmacol. Exp. Ther., August 1, 2006; 318(2): 604 - 610. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 K. J. Miller SEROTONIN 5-HT2C RECEPTOR AGONISTS: POTENTIAL FOR THE TREATMENT OF OBESITY Mol. Interv., October 1, 2005; 5(5): 282 - 291. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. L. Murphy, A. Lerner, G. Rudnick, and K.-P. Lesch Serotonin Transporter: Gene, Genetic Disorders, and Pharmacogenetics Mol. Interv., April 1, 2004; 4(2): 109 - 123. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 B. Bottalico, R. Pilka, I. Larsson, B. Casslen, K. Marsal, and S. R. Hansson Plasma membrane and vesicular monoamine transporters in normal endometrium and early pregnancy decidua Mol. Hum. Reprod., July 1, 2003; 9(7): 389 - 394. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. Lotharius, S. Barg, P. Wiekop, C. Lundberg, H. K. Raymon, and P. Brundin Effect of Mutant alpha -Synuclein on Dopamine Homeostasis in a New Human Mesencephalic Cell Line J. Biol. Chem., October 4, 2002; 277(41): 38884 - 38894. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R. B. Rothman, M. A. Ayestas, C. M. Dersch, and M. H. Baumann Aminorex, Fenfluramine, and Chlorphentermine Are Serotonin Transporter Substrates : Implications for Primary Pulmonary Hypertension Circulation, August 24, 1999; 100(8): 869 - 875. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. K. Weatherspoon and L. L. Werling Modulation of Amphetamine-Stimulated [3H]Dopamine Release from Rat Pheochromocytoma (PC12) Cells by sigma Type 2 Receptors J. Pharmacol. Exp. Ther., April 1, 1999; 289(1): 278 - 284. [Abstract] [Full Text]
|
|
|
|
 |
|
 S. R. Jones, R. R. Gainetdinov, R. M. Wightman, and M. G. Caron Mechanisms of Amphetamine Action Revealed in Mice Lacking the Dopamine Transporter J. Neurosci., March 15, 1998; 18(6): 1979 - 1986. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 K.-P. Lesch Review : Serotonin Transporter and Psychiatric Disorders: Listening to the Gene Neuroscientist, January 1, 1998; 4(1): 25 - 34. [Abstract] [PDF]
|
|
|
|
|
|
L. Teng, P. A. Crooks, P. K. Sonsalla, and L. P. Dwoskin Lobeline and Nicotine Evoke [3H]Overflow from Rat Striatal Slices Preloaded with [3H]Dopamine: Differential Inhibition of Synaptosomal and Vesicular [3H]Dopamine Uptake J. Pharmacol. Exp. Ther., March 1, 1997; 280(3): 1432 - 1444. [Abstract] [Full Text]
|
|
 |
 |
 |
|
 |
 |
 |
